Cargando…

The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells

BACKGROUND: Immunotherapy has been shown to be a promising strategy against human cancers. A better understanding of the immune regulation in hepatocellular carcinoma (HCC) could help the development of immunotherapy against HCC. The epidermal growth factor receptor (EGFR) signaling is frequently ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zongcai, Ning, Fen, Cai, Yanna, Sheng, Huiying, Zheng, Ruidan, Yin, Xi, Lu, Zhikun, Su, Ling, Chen, Xiaodan, Zeng, Chunhua, Wang, Haifang, Liu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819566/
https://www.ncbi.nlm.nih.gov/pubmed/34236149
http://dx.doi.org/10.1002/cac2.12117
_version_ 1783639032678318080
author Liu, Zongcai
Ning, Fen
Cai, Yanna
Sheng, Huiying
Zheng, Ruidan
Yin, Xi
Lu, Zhikun
Su, Ling
Chen, Xiaodan
Zeng, Chunhua
Wang, Haifang
Liu, Li
author_facet Liu, Zongcai
Ning, Fen
Cai, Yanna
Sheng, Huiying
Zheng, Ruidan
Yin, Xi
Lu, Zhikun
Su, Ling
Chen, Xiaodan
Zeng, Chunhua
Wang, Haifang
Liu, Li
author_sort Liu, Zongcai
collection PubMed
description BACKGROUND: Immunotherapy has been shown to be a promising strategy against human cancers. A better understanding of the immune regulation in hepatocellular carcinoma (HCC) could help the development of immunotherapy against HCC. The epidermal growth factor receptor (EGFR) signaling is frequently activated in HCC and plays important roles in tumorigenesis. However, its role in HCC immunity is still largely unknown. This study aimed to investigate the impact of EGFR signaling on programmed death‐ligand 1 (PD‐L1) and human leukocyte antigen class‐I (HLA‐I) expression in HCC cells and its underlying mechanisms. METHODS: The expression of phosphorylated EGFR (p‐EGFR), PD‐L1, and HLA‐I (HLA‐ABC) in HCC specimens was detected by immunohistochemistry, and their correlations were analyzed. PD‐L1 and HLA‐ABC expression in EGFR‐activated HCC cells were detected by quantitative real‐time PCR, Western blotting, and flow cytometry, and T cell‐mediated lysis was performed to test the immunosuppressive effects of PD‐L1 and HLA‐ABC alterations in HCC cells. Furthermore, the underlying mechanisms of EGFR activation‐induced PD‐L1 up‐regulation and HLA‐ABC down‐regulation were explored by animal experiments, luciferase reporter assay, and gene gain‐ and loss‐of‐function studies. RESULTS: p‐EGFR was positively correlated with PD‐L1 and negatively correlated with HLA‐ABC expression in HCCs. EGFR activation by its ligand EGF up‐regulated PD‐L1 and down‐regulated HLA‐ABC in HCC cells, which was functionally important and could be abolished by the EGFR inhibitor, gefitinib, both in vitro and in vivo. Mechanistically, enhanced P38 mitogen‐activated protein kinase (MAPK) activation down‐regulated microRNA‐675‐5p (miR‐675‐5p) and up‐regulated glycolysis‐related enzyme hexokinase 2 (HK2); miR‐675‐5p down‐regulation enhanced the stability of PD‐L1 mRNA probably via the 3’‐untranslated region (3’‐UTR) of PD‐L1 and thereby caused PD‐L1 accumulation, and HK2 up‐regulation enhanced aerobic glycolysis and mediated a decrease in HLA‐ABC. CONCLUSIONS: The EGFR‐P38 MAPK axis could up‐regulate PD‐L1 through miR‐675‐5p and down‐regulate HLA‐ABC via HK2 in HCC cells. Our study reveals a novel signaling network that may cause immune suppression in HCC and suggests that EGFR signaling can be targeted for HCC immunotherapy.
format Online
Article
Text
id pubmed-7819566
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78195662021-01-29 The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells Liu, Zongcai Ning, Fen Cai, Yanna Sheng, Huiying Zheng, Ruidan Yin, Xi Lu, Zhikun Su, Ling Chen, Xiaodan Zeng, Chunhua Wang, Haifang Liu, Li Cancer Commun (Lond) Original Articles BACKGROUND: Immunotherapy has been shown to be a promising strategy against human cancers. A better understanding of the immune regulation in hepatocellular carcinoma (HCC) could help the development of immunotherapy against HCC. The epidermal growth factor receptor (EGFR) signaling is frequently activated in HCC and plays important roles in tumorigenesis. However, its role in HCC immunity is still largely unknown. This study aimed to investigate the impact of EGFR signaling on programmed death‐ligand 1 (PD‐L1) and human leukocyte antigen class‐I (HLA‐I) expression in HCC cells and its underlying mechanisms. METHODS: The expression of phosphorylated EGFR (p‐EGFR), PD‐L1, and HLA‐I (HLA‐ABC) in HCC specimens was detected by immunohistochemistry, and their correlations were analyzed. PD‐L1 and HLA‐ABC expression in EGFR‐activated HCC cells were detected by quantitative real‐time PCR, Western blotting, and flow cytometry, and T cell‐mediated lysis was performed to test the immunosuppressive effects of PD‐L1 and HLA‐ABC alterations in HCC cells. Furthermore, the underlying mechanisms of EGFR activation‐induced PD‐L1 up‐regulation and HLA‐ABC down‐regulation were explored by animal experiments, luciferase reporter assay, and gene gain‐ and loss‐of‐function studies. RESULTS: p‐EGFR was positively correlated with PD‐L1 and negatively correlated with HLA‐ABC expression in HCCs. EGFR activation by its ligand EGF up‐regulated PD‐L1 and down‐regulated HLA‐ABC in HCC cells, which was functionally important and could be abolished by the EGFR inhibitor, gefitinib, both in vitro and in vivo. Mechanistically, enhanced P38 mitogen‐activated protein kinase (MAPK) activation down‐regulated microRNA‐675‐5p (miR‐675‐5p) and up‐regulated glycolysis‐related enzyme hexokinase 2 (HK2); miR‐675‐5p down‐regulation enhanced the stability of PD‐L1 mRNA probably via the 3’‐untranslated region (3’‐UTR) of PD‐L1 and thereby caused PD‐L1 accumulation, and HK2 up‐regulation enhanced aerobic glycolysis and mediated a decrease in HLA‐ABC. CONCLUSIONS: The EGFR‐P38 MAPK axis could up‐regulate PD‐L1 through miR‐675‐5p and down‐regulate HLA‐ABC via HK2 in HCC cells. Our study reveals a novel signaling network that may cause immune suppression in HCC and suggests that EGFR signaling can be targeted for HCC immunotherapy. John Wiley and Sons Inc. 2021-01-01 /pmc/articles/PMC7819566/ /pubmed/34236149 http://dx.doi.org/10.1002/cac2.12117 Text en © 2020 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Liu, Zongcai
Ning, Fen
Cai, Yanna
Sheng, Huiying
Zheng, Ruidan
Yin, Xi
Lu, Zhikun
Su, Ling
Chen, Xiaodan
Zeng, Chunhua
Wang, Haifang
Liu, Li
The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells
title The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells
title_full The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells
title_fullStr The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells
title_full_unstemmed The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells
title_short The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells
title_sort egfr‐p38 mapk axis up‐regulates pd‐l1 through mir‐675‐5p and down‐regulates hla‐abc via hexokinase‐2 in hepatocellular carcinoma cells
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819566/
https://www.ncbi.nlm.nih.gov/pubmed/34236149
http://dx.doi.org/10.1002/cac2.12117
work_keys_str_mv AT liuzongcai theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT ningfen theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT caiyanna theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT shenghuiying theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT zhengruidan theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT yinxi theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT luzhikun theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT suling theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT chenxiaodan theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT zengchunhua theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT wanghaifang theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT liuli theegfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT liuzongcai egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT ningfen egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT caiyanna egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT shenghuiying egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT zhengruidan egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT yinxi egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT luzhikun egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT suling egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT chenxiaodan egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT zengchunhua egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT wanghaifang egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells
AT liuli egfrp38mapkaxisupregulatespdl1throughmir6755panddownregulateshlaabcviahexokinase2inhepatocellularcarcinomacells